Physician profile
Xiantuo Wu
NPI 1639397631
$35,029.56
in general payments reported to CMS, 2019-2025
28 companies · $12K in 2025
The $12K reported for 2025 was more than what 89% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,913 · 2020: $260 · 2021: $3,563 · 2022: $165 · 2023: $3,938 · 2024: $8,499 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Travel and Lodging: $4,711 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Food and Beverage: $1,882 · Education: $718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,818.00 |
| Travel and Lodging | $4,710.93 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Food and Beverage | $1,881.94 |
| Education | $717.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $11,519.21 | 2019-2025 | Monjuvi |
| Astrazeneca Pharmaceuticals LP | $7,580.77 | 2019-2025 | Imfinzi, Tagrisso |
| Karyopharm Therapeutics INC. | $4,213.15 | 2021-2025 | Xpovio |
| Avyxa Pharma, LLC | $4,205.35 | 2025 | |
| Adc Therapeutics America, INC. | $2,000.00 | 2024 | |
| Pfizer INC. | $1,750.00 | 2021 | |
| Beigene USA, INC. | $675.00 | 2024 | Brukinsa |
| Janssen Biotech, INC. | $449.80 | 2021-2025 | Darzalex, Tecvayli, Talvey |
| Seagen INC. | $444.22 | 2019-2025 | Tukysa |
| Allergan, INC. | $399.08 | 2019 | |
| Cardinal Health 110 LLC | $275.00 | 2025 | |
| Glaxosmithkline, LLC. | $204.86 | 2021-2024 | Zejula |
| Sobi, INC | $188.10 | 2024 | |
| Abbvie INC. | $173.58 | 2020-2024 | Venclexta |
| Verastem, INC. | $124.28 | 2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $122.81 | 2024 | |
| Stemline Therapeutics INC. | $121.81 | 2023 | Orserdu |
| Aveo Pharmaceuticals, INC. | $99.99 | 2024 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2021 | |
| Eisai INC. | $99.42 | 2023 | |
| Gilead Sciences, INC. | $99.04 | 2022 | |
| Coherus Oncology, INC. | $59.59 | 2025 | Loqtorzi |
| Daiichi Sankyo INC. | $29.44 | 2023 | Enhertu |
| Regeneron Healthcare Solutions, INC. | $27.90 | 2021 | |
| Exelixis INC. | $24.42 | 2019 | |
| Janssen Pharmaceuticals, INC | $20.43 | 2019 | |
| Celgene Corporation | $18.51 | 2020 | |
| Biocomposites INC | $3.85 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xiantuo Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.